Trial of Intraperitoneal (IP) Oxaliplatin in Combination With Intravenous FOLFIRI
Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
This is a Phase I dose escalation study to determine how much chemotherapy can be safely
administered into the abdomen while experiencing the fewest possible side effects.